Home › Urothelial (Transitional Cell) Carcinoma › District of Columbia
Urothelial (Transitional Cell) Carcinoma clinical trials in District of Columbia
7 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in District of Columbia.
Cities in District of Columbia
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- MedStar Georgetown University Hospital, Washington D.C.
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- Sibley Memorial Hospital Pharmacy Department, Washington D.C.
- Sibley Memorial Hospital, Washington D.C.
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07421700A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Johns Hopkins Sibley Memorial Hospital, Washington D.C.
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277413A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- MedStar Washington Hospital Center, Washington D.C.
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07218380A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
- Research Site, Washington D.C.
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07815665A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
- Medstar Washington Hospital Center, Washington D.C.
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06774131A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- Medstar Washington Hospital Center, Washington D.C.
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT04879329From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.